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Weanalyzedtheoutcomeofaseriesof19newlydiagnosedpatientswithacutepromyelocyticleukemiatreatedwithAIDAmodiﬁed
protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients
had induction failure due to death during induction. Ten of eleven patients in CR achieved molecular remission after induction
therapyandallthe8patientshadmolecularremissionafterconsolidation.Eightpatientscompletedthethreeconsolidationcourses
as scheduled and then proceeded to maintenance therapy. After a median follow up of 52 months, no molecular or hematological
relapse has occurred. The 4-year disease-free survival is 82%. The study showed the antileukemic eﬃcacy of mitoxantrone and that
it could be used as a reasonable option in anthracycline-based strategies in APL.
The simultaneous administration of all-transretinoic acid
(ATRA) and anthracycline-based chemotherapy is currently
considered the standard induction therapy in newly diag-
nosed patients with acute promyelocytic leukemia (APL),
leading to complete remission (CR) rate greater than 90%
and potential cure in up to 80% [1, 2]. Once in CR,
the standard postremission therapy consists of 2-3 cycles
of anthracycline-based chemotherapy followed by ATRA-
containing maintenance therapy [3]. Most common anthra-
cyclines used are idarubicin or daunorubicin. The aim of
this study was to evaluate the clinical outcome of APL
patients treated with a modiﬁed AIDA protocol [4]i nw h i c h
idarubicin was replaced by mitoxantrone at an equivalent
dose (1mg of idarubicin = 1mg of mitoxantrone). This
replacement was made due to the economical diﬃculty of
buying idarubicin in our center.
We analyzed the outcome of a series of newly diag-
nosed patients with APL treated at the Hematology Cen-
ter of the University of Campinas. Diagnosis was con-
ﬁrmed by the presence of t(15;17) in cytogenetic stud-
ies and/or PML/RARα gene rearrangement [5, 6]. Induc-
tion chemotherapy consisted of intravenous mitoxantrone
(10mg/m2)o nd a y s2 ,4 ,6 ,a n d8a n do r a lA T R Af r o m
day 1 (45mg/m2/d) until complete remission. Patients in
CR received three cycles of consolidation therapy: cycle one:
mitoxantrone 5mg/m2 and cytarabine 1g/m2 IV(days 1–4);
cycle 2: mitoxantrone 10mg/m2 and vepeside 100mg/m2
IV (days 1–5); cycle 3: mitoxantrone 10mg/m2, cytarabine
150mg/m2/8h IV (days 1–5), and tioguanine 70mg/m2/8h
(days 1–5). Maintenance therapy consisted of oral ATRA
(45mg/m2/d) during 14 days every 3 months for 2 years.
A c t u a r i a ls u r v i v a lc u r v e sw e r ec a l c u l a t e db yt h eK a p l a n -
Meier method.
BetweenMarch1999andMay2006,19patientswithAPL
were treated with the previously described AIDA modiﬁed
protocol with mitoxantrone replacing idarubicin. The main
clinical and biologic characteristics of the 19 patients are
described in Table 1. Eleven patients achieved morphologic
CR (58%). The remaining 8 patients had induction failure
due to death during induction, 4 attributable to cerebral
or pulmonary hemorrhage (50%), 3 to infection, and one
to diﬀerentiation syndrome. Eight deaths occurred among
the 10 patients with white blood cell count (WBC) at
presentation greater than 2.7 × 109/L (median), while the
remaining3deathsoccurredamong9patientswithWBCless
than 2.7 × 109/L( P = .01). Ten of 11 patients who achieved2 Advances in Hematology
Table 1: Demographic and baseline characteristics of the study
population.
Characteristic Total
Median (range) No. (%)
No. of patients 19 (100)
Age, year 40 (14–68)
15 or younger 1 (5)
16–60 17 (90)
61 or older 1 (5)
Gender
Male 10 (53)
Female 9 (47)
WBC count, ×109/L 2.7 (0.4–49.0)
Less than 5 10 (52)
5–10 3 (16)
11–50 6 (32)
PB blast count, ×109/L 60 (1–98)
Less than 30 3 (16)
30 or higher 16 (84)
Platelet count, ×109/L 13 (4–85)
Less than 40 15 (79)
40 or higher 4 (21)
Hemoglobin, g/dL 8.8 (5.0–10.6)
Less than 10 17 (90)
10 or higher 2 (10)
Creatinine, mg/dL 0.92 (0.59–1.47)
Less than 1.4 18 (95)
1.4 or higher 1 (5)
Coagulopathy
No 7 (37)
Yes 12 (63)
Morphologic subtype
Hypergranular 15 (79)
Microgranular 4 (21)
Relapse risk group
Low 3 (16)
Intermediate 11 (58)
High 5 (26)
PML/RARα isoform
BCR1/BCR2 10 (59)
BCR3 7 (41)
Not available 2
CR proceeded to consolidation therapy. One patient died
frompulmonaryMycobacteriumtuberculosisinfectionbefore
consolidation. Two of 10 patients died during consolidation,
one after the ﬁrst cycle and one after the third cycle, both due
to infection. The remaining 8 patients completed the three
consolidation courses as scheduled, and then proceeded to
maintenance therapy. One patient interrupted maintenance
therapy due to a second episode of pancreatitis. Ten of
eleven evaluable patients achieved molecular remission after
induction therapy, and all the 8 patients had molecular
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Figure 1: Disease-free survival of APL patients.
remissionafterconsolidation.Afteramedianfollow-upof52
months,nomolecularorhematologicalrelapsehasoccurred.
The 4-year disease-free survival is 82% (Figure 1) and the
cumulative incidence of relapse was 0% in this population.
The problem of the high mortality rate during induction
was recently addressed in a retrospective study of Brazilian
APL patients treated in diﬀerent centers [7]a n dp r o b a b l y
was related to a deﬁcient supportive therapy. Apart from
conﬁrming the high mortality during induction and consol-
idation, our study provides other data that we consider of
interest to be reported.
Despite the small sample size, the present study shows
the antileukemic eﬃcacy of mitoxantrone in APL, leading to
a high rate of molecular remission after induction therapy
and the lack of relapses in those patients who completed
inductionandconsolidationtherapy.Thisstudysuggeststhat
mitoxantrone could be considered as an alternative to other
anthracyclines in this disease if these drugs are not available.
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